Drug profile · INN
belimumab
BENLYSTA
belimumab (BENLYSTA) is a tumor necrosis factor ligand superfamily member 13b inhibitor. Route of administration: injection. Current US regulatory status: approved.
Drug details — belimumab
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L04)
- Route
- INJECTION
- Patents
- 0
- Programs
- 9
- Data quality
- 0.84
Quick answer
belimumab (BENLYSTA) is a tumor necrosis factor ligand superfamily member 13b inhibitor. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Tumor necrosis factor ligand superfamily member 13B inhibitor
Primary target: Tumor necrosis factor ligand superfamily member 13B
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is belimumab?
belimumab (BENLYSTA) is a tumor necrosis factor ligand superfamily member 13b inhibitor. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for belimumab?
BENLYSTA is a marketed brand name for belimumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of belimumab?
belimumab has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.